Podocalyxin是人子宫内膜上皮容受性的关键负调控因子
该研究通过原代人子宫内膜上皮细胞蛋白质组学发现PCX,并验证其在月经周期中的表达模式及孕酮调控。PCX在非容受期子宫内膜上皮顶端表达,分泌中期管腔上皮选择性下调,孕酮可抑制其表达。过表达PCX抑制人胚胎类似物附着与侵入,表明PCX是上皮容受性的重要负调控因子。
要点
- PCX在非容受期子宫内膜上皮顶端表达,分泌中期管腔上皮选择性下调。
- 孕酮可抑制原代子宫内膜上皮细胞中PCX表达。
- 过表达PCX抑制人胚胎类似物的附着与侵入。
核心结论
- PCX是子宫内膜上皮容受性的关键负调控因子,其管腔上皮特异性下调可能是容受性建立的关键步骤。
研究设计与样本
- 研究纳入原代人子宫内膜上皮细胞(n=9,合并为3池)进行质膜蛋白质组学分析。
- 免疫组化分析月经周期子宫内膜PCX表达(n=23)。
- 原代上皮细胞培养中雌二醇和孕酮处理,RT-PCR(n=5)和western blot(n=4)分析PCX调控。
- Ishikawa细胞过表达PCX,体外附着(n=3-5)和侵入(n=4-6)模型评估功能。
主要发现
- PCX表达于非容受期子宫内膜所有上皮和内皮细胞顶端表面,分泌中期管腔上皮选择性下调。
- 孕酮可抑制原代上皮细胞中PCX表达,提示其介导体内管腔PCX下调。
- Ishikawa单层过表达PCX抑制人胚胎类似物的附着和穿透。
关键数值与推荐
- 统计学显著性设定为*P ≤ 0.05和**P ≤ 0.01(Mann-Whitney U检验和ANOVA)。
临床怎么用
- PCX可能作为评估子宫内膜容受性的新型标志物。
- PCX可能作为监测孕酮作用的生物标志物,用于优化黄体支持方案。
局限性
- 原代上皮细胞包含管腔和腺上皮细胞混合物,因缺乏特异性标志物无法进一步纯化。
- 功能模型使用人滋养层球状体和Ishikawa细胞,未来需用人囊胚和原代上皮细胞验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: How is endometrial epithelial receptivity, particularly adhesiveness, regulated at the luminal epithelial surface for embryo implantation in the human? SUMMARY ANSWER: Podocalyxin (PCX), a transmembrane protein, was identified as a key negative regulator of endometrial epithelial receptivity; specific downregulation of PCX in the luminal epithelium in the mid-secretory phase, likely mediated by progesterone, may act as a critical step in converting endometrial surface from a non-receptive to an implantation-permitting state. WHAT IS KNOWN ALREADY: The human endometrium must undergo major molecular and cellular changes to transform from a non-receptive to a receptive state to accommodate embryo implantation. However, the fundamental mechanisms governing receptivity, particularly at the luminal surface where the embryo first interacts with, are not well understood. A widely held view is that upregulation of adhesion-promoting molecules is important, but the details are not well characterized. STUDY DESIGN, SIZE, DURATION: This study first aimed to identify novel adhesion-related membrane proteins with potential roles in receptivity in primary human endometrial epithelial cells (HEECs). Further experiments were then conducted to determine candidates' in vivo expression pattern in the human endometrium across the menstrual cycle, regulation by progesterone using cell culture, and functional importance in receptivity using in vitro human embryo attachment and invasion models. PARTICIPANTS/MATERIALS, SETTING, METHODS: Primary HEECs (n = 9) were isolated from the proliferative phase endometrial tissue, combined into three pools, subjected to plasma membrane protein enrichment by ultracentrifugation followed by proteomics analysis, which led to the discovery of PCX as a novel candidate of interest. Immunohistochemical analysis determined the in vivo expression pattern and cellular localization of PCX in the human endometrium across the menstrual cycle (n = 23). To investigate whether PCX is regulated by progesterone, the master driver of endometrial differentiation, primary HEECs were treated in culture with estradiol and progesterone and analyzed by RT-PCR (n = 5) and western blot (n = 4). To demonstrate that PCX acts as a negative regulator of receptivity, PCX was overexpressed in Ishikawa cells (a receptive line) and the impact on receptivity was determined using in vitro attachment (n = 3-5) and invasion models (n = 4-6), in which an Ishikawa monolayer mimicked the endometrial surface and primary human trophoblast spheroids mimicked embryos. Mann-Whitney U-test and ANOVA analyses established statistical significance at *P ≤ 0.05 and **P ≤ 0.01. MAIN RESULTS AND THE ROLE OF CHANCE: PCX was expressed on the apical surface of all epithelial and endothelial cells in the non-receptive endometrium, but selectively downregulated in the luminal epithelium from the mid-secretory phase coinciding with the establishment of receptivity. Progesterone was confirmed to be able to suppress PCX in primary HEECs, suggesting this hormone likely mediates the downregulation of luminal PCX in vivo for receptivity. Overexpression of PCX in Ishikawa monolayer inhibited not only the attachment but also the penetration of human embryo surrogates, demonstrating that PCX acts as an important negative regulator of epithelial receptivity for implantation. LIMITATIONS, REASONS FOR CAUTION: Primary HEECs isolated from the human endometrial tissue contained a mixture of luminal and glandular epithelial cells, as further purification into subtypes was not possible due to the lack of specific markers. Future study would need to investigate how progesterone differentially regulates PCX in endometrial epithelial subtypes. In addition, this study used primary human trophoblast spheroids as human embryo mimics and Ishikawa as endometrial epithelial cells in functional models, future studies with human blastocysts and primary epithelial cells would further validate the findings. WIDER IMPLICATIONS OF THE FINDINGS: The findings of this study add important new knowledge to the understanding of human endometrial remodeling for receptivity. The identification of PCX as a negative regulator of epithelial receptivity and the knowledge that its specific downregulation in the luminal epithelium coincides with receptivity development may provide new avenues to assess endometrial receptivity and individualize endometrial preparation protocols in assisted reproductive technology (ART). The study also discovered PCX as progesterone target in HEECs, identifying a potentially useful functional biomarker to monitor progesterone action, such as in the optimization of progesterone type/dose/route of administration for luteal support. STUDY FUNDING/COMPETING INTEREST(S): Study funding was obtained from ESHRE, Monash IVF and NHMRC. LR reports potential conflict of interests (received grants from Ferring Australia; personal fees from Monash IVF Group and Ferring Australia; and non-financial support from Merck Serono, MSD, and Guerbet outside the submitted work. LR is also a minority shareholder and the Group Medical Director for Monash IVF Group, a provider of fertility preservation services). The remaining authors have no potential conflict of interest to declare. TRIAL REGISTRATION NUMBER: NA.
引用
- Paule SG, Heng S, Samarajeewa N, et al. Podocalyxin is a key negative regulator of human endometrial epithelial receptivity for embryo implantation. Hum Reprod. 2021. PMID: 33822049. doi:10.1093/humrep/deab032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。